Navigation Links
Mood-modifying drugs for humans also alter fish behavior
Date:2/14/2013

This release is available in Arabic, French, Japanese, Spanish, Swedish, and Chinese.

Pharmaceutical drugs that end up in the world's waterways after being excreted, flushed and treated at wastewater treatment plants may lead to unexpected ecological impacts, according to a new study of wild European perch. Tomas Brodin and colleagues from Ume University in Sweden discovered that the fish ate faster, became bolder and acted less social after being subjected to an anxiety-moderating drug, known as Oxazepam.

The psychiatric drug is used to treat anxiety in humans. But, Oxazepam residues often wind up in natural aquatic systems, downstream from sewage treatment plants, where their effects on ecosystems have been unknown. Now, Brodin and the other researchers have dosed wild perch with amounts of Oxazepam equivalent to those found in Sweden's rivers and streams, and their results suggest that even small amounts of the drug can alter the behavior and the foraging rates of these fish.

The related report appears in the 15 February issue of the journal Science, which is published by AAAS, the nonprofit science society.

"While alone, fish that were exposed to Oxazepam dared to leave safe refuge and enter novel, potentially dangerous areas," explained Brodin. "In contrast, unexposed fish stayed hidden in their refuge. The exposed fish seemed much less stressed and scared, behaving calmer and bolder."

Perch that were exposed to the drug also devoured their food quicker than unexposed fisha behavioral quirk that the researchers say could alter the composition of species in the water and lead to ecological events, such as increased algal blooming, over time. Since fish are generally integral pieces of their food webs, changes in their eating patterns could disturb ecological balances, according to the researchers.

The fish that were given Oxazepam during the study also became anti-social, distancing themselves from other perch and putting themselves at greater risk of predation. "Perch that were exposed to Oxazepam lost interest in hanging out with the group, and some even stayed as far away from the group as possible," explained Brodin.

The fish in the study accumulated concentrations of the drug in their muscle tissues that were comparable to those found in wild fish, according to the researchers. So it's likely that the fish in Sweden's surface waters, many of which are being exposed to similarly diluted doses of Oxazepam, may be experiencing changes in their behavior and feeding rates as well, they say.

This study by Brodin and his colleagues singled out a particular psychiatric drug that has been found in natural systems. But, a veritable cocktail of drugs can be found in waterways worldwide, making the discovery of Oxazepam's effects on fish that much more important.

More comprehensive studies are needed before general conclusions can be drawn about how such pharmaceutically induced changes to behavior might affect ecosystems, but these current findings suggest that the concentrations of Oxazepam in Sweden's surface waters could have unexpected ecological and evolutionary consequences over time.

"The solution to this problem isn't to stop medicating people who are ill but to try to develop sewage treatment plants that can capture environmentally hazardous drugs," concluded Jerker Fick, a co-author of the Science report, in a press release from Ume University.


'/>"/>

Contact: Natasha Pinol
npinol@aaas.org
202-326-6440
American Association for the Advancement of Science
Source:Eurekalert  

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Nanopills release drugs directly from the inside of cells
3. Genetic variation in East Asians found to explain resistance to cancer drugs
4. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
5. Internet and new drugs: A challenge for public health
6. Study raises questions about use of anti-epilepsy drugs in newborns
7. Drugs from lizard saliva reduces the cravings for food
8. A new method detects traces of veterinary drugs in baby food
9. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
10. MIT-designed cooler preserves tuberculosis drugs, records doses
11. Arsenic for better drugs and cleaner crops
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mood-modifying drugs for humans also alter fish behavior
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
(Date:2/15/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. ... disease risk in future generations. In his new role, Matt will be responsible ...
Breaking Biology Technology: